Rituximab Regimen Improves Survival in Children With Aggressive B-Cell Lymphoma

Adding rituximab (Rituxan, Truxima) to chemotherapy may be a new standard for treating children and young adults newly diagnosed with aggressive B-cell lymphoma, according to findings from a randomized, international, phase 3 trial.

Read more: https://www.ajmc.com/newsroom/rituximab-regimen-improves-survival-in-children-with-aggressive-bcell-lymphoma